Final Up to date on September 15, 2022 by GlobeNewsWire
LA JOLLA, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical firm traded on the NASDAQ International Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Inventory Alternate (Code Quantity: 4875), at present introduced that it is going to be conducting one-on-one digital conferences with institutional buyers as a part of the Lytham Companions Fall 2022 Investor Convention. The occasion is happening nearly on September 28 – 29, 2022.
Yuichi Iwaki, MD, PhD, President and Chief Govt Officer, and Geoffrey O’Brien, JD/MBA, Vice President and Govt Officer, might be out there for one-on-one conferences at this convention and buyers could request a one-on-one assembly by contacting Joe Diaz of Lytham Companions by telephone at (602) 889-9660, by e mail at email@example.com or by registering at https://www.lythampartners.com/fall2022invreg/.
MediciNova, Inc. is a clinical-stage biopharmaceutical firm growing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative ailments. Based mostly on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with a number of mechanisms of motion and powerful security profiles, MediciNova has 11 applications in scientific improvement. MediciNova’s lead asset, MN-166 (ibudilast), is presently in Part 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Part 3-ready for progressive a number of sclerosis (MS). MN-166 (ibudilast) can be being evaluated in Part 2 trials in glioblastoma and substance dependence. MN-001 (tipelukast) was evaluated in a Part 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Part 2 trial in non-alcoholic fatty liver illness (NAFLD) is ongoing. MediciNova has a robust monitor document of securing investigator-sponsored scientific trials funded by way of authorities grants.
Statements on this press launch that aren’t historic in nature represent forward-looking statements inside the that means of the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. These forward-looking statements embrace, with out limitation, statements relating to the long run improvement and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements could also be preceded by, adopted by, or in any other case embrace the phrases “believes,” “expects,” “anticipates,” “intends,” “estimates,” “tasks,” “can,” “might,” “could,” “will,” “would,” “contemplating,” “planning” or related expressions. These forward-looking statements contain plenty of dangers and uncertainties which will trigger precise outcomes or occasions to vary materially from these expressed or implied by such forward-looking statements. Elements which will trigger precise outcomes or occasions to vary materially from these expressed or implied by these forward-looking statements embrace, however usually are not restricted to, dangers of acquiring future accomplice or grant funding for improvement of MN-166, MN-001, MN-221, and MN-029 and dangers of elevating ample capital when wanted to fund MediciNova’s operations and contribution to scientific improvement, dangers and uncertainties inherent in scientific trials, together with the potential price, anticipated timing and dangers related to scientific trials designed to satisfy FDA steerage and the viability of additional improvement contemplating these components, product improvement and commercialization dangers, the uncertainty of whether or not the outcomes of scientific trials might be predictive of ends in later levels of product improvement, the danger of delays or failure to acquire or keep regulatory approval, dangers related to the reliance on third events to sponsor and fund scientific trials, dangers relating to mental property rights in product candidates and the power to defend and implement such mental property rights, the danger of failure of the third events upon whom MediciNova depends to conduct its scientific trials and manufacture its product candidates to carry out as anticipated, the danger of elevated price and delays as a consequence of delays within the graduation, enrollment, completion or evaluation of scientific trials or important points relating to the adequacy of scientific trial designs or the execution of scientific trials, and the timing of anticipated filings with the regulatory authorities, MediciNova’s collaborations with third events, the supply of funds to finish product improvement plans and MediciNova’s capability to acquire third occasion funding for applications and lift ample capital when wanted, and the opposite dangers and uncertainties described in MediciNova’s filings with the Securities and Alternate Fee, together with its annual report on Type 10-Ok for the yr ended December 31, 2021 and its subsequent periodic experiences on Type 10-Q and present experiences on Type 8-Ok. Undue reliance shouldn’t be positioned on these forward-looking statements, which converse solely as of the date hereof. MediciNova disclaims any intent or obligation to revise or replace these forward-looking statements.
Geoff O’BrienVice PresidentMediciNova, Inc.firstname.lastname@example.org